MARKET

CGEN

CGEN

Compugen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.65
-0.08
-0.45%
Closed 16:00 09/22 EDT
OPEN
17.90
PREV CLOSE
17.73
HIGH
18.20
LOW
17.32
VOLUME
2.08M
TURNOVER
--
52 WEEK HIGH
19.90
52 WEEK LOW
3.828
MARKET CAP
1.46B
P/E (TTM)
-47.3190
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Our Take On Compugen's (NASDAQ:CGEN) CEO Salary
This article will reflect on the compensation paid to Anat Cohen-Dayag who has served as CEO of Compugen Ltd...
Simply Wall St. · 09/12 15:59
Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors
Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers Squibb’s (BMY) Opdivo and their investigational anti-TIGIT antibody-BMS-986207 for solid tumors.Compugen’s (CGEN) early-stage study is evaluating the safety
SmarterAnalyst · 09/09 06:35
Compugen launches early-stage combination study for COM701 in solid tumors
Dosing is underway in Compugen's ([[CGEN]] -3.1%) Phase 1/2 study evaluating the triple combination of Compugen's COM701, with Bristol Myers Squibb's Opdivo (nivolumab), and their investigational anti-TIGIT antibody, BMS-986207, for solid
Seekingalpha · 09/08 14:05
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
PR Newswire · 09/08 12:00
Compugen Doses First Patient In Phase 1/2 Triple Combination Study Of COM701 With Bristol Myers Squibb's Opdivo And Anti-TIGIT Antibody
HOLON, Israel, Sept. 8, 2020 /PRNewswire/ --Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapycompany and a leader in predictive target discovery, today announced that the first
Benzinga · 09/08 11:14
Compugen to Present at Upcoming September 2020 Investor Conferences
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the following upcoming virtual investor conferences:
PR Newswire · 09/03 12:00
Evogene: Hidden Gems Of Computational Predictive Biology (Part 3 Of 4) - Ag Plenus (Novel Herbicides And Pesticides)
Evogene's 100% owned subsidiary AgPlenus utilizes Evogene's computational predictive biology platform to develop Ag-Chemicals (novel herbicides, insecticides and other crop control products).AgPlenus has entered into a number of collaboration licensing agreements with various multi-national companies including BASF, Corteva, and ICL. ARK Invest just announced a $7 million investment in EVGN.AgPlenus has a portfolio of a novel mode of action herbicides and insecticides. With more than 10 "Hits", its most advanced novel herbicide will likely be a "Lead" in 2020.There is an immediate need for novel mode of action herbicides, insecticides and other crop control products. These are enormous markets estimated to be in excess of $70 billion by 2022.Evogene remains grossly undervalued when taking into account its computational platform, cash balance, internal division, and 4 valuable subsidiaries. This is the 3rd of a 4-part series on Evogene. This article's focus is on Evogene's 100% subsidiary AgPlenus.
Seekingalpha · 09/02 14:48
Compugen nabs new U.S. patent for COM902
The USPTO has granted Compugen (CGEN) a new patent for COM902, its immuno-oncology therapeutic antibody targeting TIGIT. U.S. Patent No. 10,751,415, titled "Anti-TIGIT Antibodies, Anti-PVRIG Antibodies and Combinations Thereof," relates
Seekingalpha · 08/28 13:23
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CGEN. Analyze the recent business situations of Compugen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CGEN stock price target is 19.75 with a high estimate of 28.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 106
Institutional Holdings: 39.46M
% Owned: 47.71%
Shares Outstanding: 82.69M
TypeInstitutionsShares
Increased
29
7.19M
New
42
3.43M
Decreased
16
3.17M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.48%
Pharmaceuticals & Medical Research
+0.12%
Key Executives
Chairman/Director
Paul Sekhri
President/Chief Executive Officer/Director
Anat Cohen-Dayag
Chief Financial Officer
Ari Krashin
Vice President
Zurit Levine
Vice President - Research & Development
John Hunter
Other
Henry Adewoye
Director
Jean-Pierre Bizzari
Director
Gilead Halevy
Director
Kinneret Livnat Savitsky
Director
Eran Perry
Director
Michal Preminger
Director
Sanford Zweifach
Independent Director
Yair Aharonowitz
Independent Director
Ruth Arnon
Independent Director
Arie Ovadia
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Compugen Ltd. (USA) stock information, including NASDAQ:CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.